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Abstract
Purpose The aim of this quality control study was to
assess the time to initial diagnostic procedures and the time
to the first dose of antibiotics in patients with pneumo-
coccal bacteremia, and to investigate whether the timeli-
ness of these interventions influenced outcome.
Methods We retrospectively studied patient characteris-
tics, chronological sequence of diagnostic and therapeutic
steps, and the course of disease of all patients with pneu-
mococcal bacteremia at a Swiss university hospital between
2003 and 2009, and we analyzed associations between these
factors and the length of hospital stay (LOS) and mortality.
Results A total of 102 episodes of pneumococcal bac-
teremia in 98 patients were analyzed, of whom 15.7% died
during hospitalization. The median time (interquartile
range [IQR]) to the first antibiotic dose was 4.0 (2.0–5.9) h,
and the median times (IQR]) to blood cultures, chest
radiograph, lumbar puncture, and brain computed tomog-
raphy (CT) scan or magnetic resonance imaging (MRI)
were 1.4 (0.5–3.3), 2.5 (1.2–4.2), 4.2 (2.7–7.2), and 2.3
(0.6–6.2) h, respectively. The time to diagnostic proce-
dures and therapy were not associated with LOS or death.
Risk factors for death in the univariable analysis were:
Charlson comorbidity index [odds ratio [OR] (95% confi-
dence interval) per unit increase, 1.3 (1.1–1.6)], neutrope-
nia [OR 10.1 (2.0–51.0)], human immunodeficiency virus
(HIV) infection [OR 3.9 (1.1–13.8)], chronic respiratory
disease [OR 4.4 (1.2–16.0)], chronic liver disease [OR 3.2
(1.0–9.7)], smoking [OR 3.8 (1.1–13.5)], injection drug
use [OR 9.7 (1.5–63.7)], and antibiotic therapy within
6 months before admission [OR 4.0 (1.3–12.5)]. The
multivariable analysis revealed age[60 years (P = 0.048)
and alcoholism (P = 0.009) as risks for prolonged LOS.
Conclusions The outcome of pneumococcal bacteremia
may be more influenced by patient characteristics than by
minor differences in the timeliness of initial diagnostic and
therapeutic measures within the first several hours after
hospital admission.
Keywords Streptococcus pneumoniae  Bacteremia 
Outcome  Sepsis  Treatment quality  Benchmark
Introduction
Streptococcus pneumoniae infections are associated with
severe morbidity and substantial mortality [1–5]. In
numerous studies, different predictors influencing the out-
come of pneumococcal bacteremia have been identi-
fied, including coronary heart disease, neutropenia, and
A.-M. Giner  S. P. Kuster  C. Ruef  B. Ledergerber 
R. Weber (&)
Division of Infectious Diseases and Hospital Epidemiology,
University Hospital Zurich and University of Zurich,











Institute of Medical Microbiology, University of Zurich,





increasing age [1, 3, 5]. On the other hand, the morbidity of
severe bacterial infections has been shown to be reduced
with the prompt administration of appropriate antibiotic
treatment [6–10]. Benchmarks for the timing of antibiotic
therapy have been proposed for different organ system
infections: treatment initiation within 4 h is considered to
be appropriate for community-acquired pneumonia in
people aged more than 65 years, and within 3 h for acute
bacterial meningitis [11, 12]. Nevertheless, data on the
association between the timeliness of initial diagnostic
procedures or the initiation of therapy and outcome are
scarce [13], and it is unknown whether specific benchmarks
are applicable in the care of patients with pneumococcal
bacteremia.
Within the antibiotic stewardship program at our hos-
pital [14], we aimed to assess the quality of the initial
management of patients with pneumococcal bacteremia,
and to compare performance and outcomes with local and
international guidelines and benchmarks [11, 12]. There-
fore, we studied the associations between the variables
‘‘time to initiation of diagnostic procedures’’ (such as
imaging, lumbar puncture, or blood culture collection),
‘‘time to initiation of antibiotic therapy’’, and in-hospital
mortality and length of hospital stay (LOS).
Patients and methods
Ethics statement
Approval by the Research Ethics Board of the Canton of
Zurich, Switzerland (address: Kantonale Ethikkommission
Zu¨rich, Sonneggstrasse 12, CH-8091 Zu¨rich, Switzerland),
was obtained. The ethics committee decided that patients’
informed consent was not required because this study was a
retrospective quality control project by infectious diseases
physicians directly involved in patient care.
Patients and setting
We performed a retrospective study at the University
Hospital Zurich, an 800-bed tertiary care teaching hospital
that covers all specialties, except pediatrics and orthope-
dics. Six intensive care units offer a full range of clinical
services in different departments of surgery and internal
medicine.
The electronic database of the Institute of Medical
Microbiology, University of Zurich, where all microbio-
logical samples of the University Hospital Zurich are pro-
cessed, was used to identify patients with the detection of
S. pneumoniae in blood cultures. All patients with a com-
munity-acquired episode of pneumococcal bacteremia
between January 1, 2003, and March 31, 2009, were eligible
for inclusion in the study. An episode of pneumococcal
bacteremia was determined by one or more blood culture
pairs positive for S. pneumoniae. Isolates from an individual
patient were considered to be a single episode if the interval
between collections of the isolates was less than 30 days.
Bacteremia was not considered to be community-
acquired if the patient was discharged from a hospital less
than 7 days before the current hospital admission, if the
first blood culture was obtained more than 1 week after
hospital admission, or if the patient had no clinical signs
and symptoms compatible with pneumococcal infection at
the time of admission. We excluded patients who were
referred from other hospitals, or who were transferred to
another hospital or discharged before the end of treatment.
Data collection
Medical records were reviewed for the following infor-
mation using a standardized data collection questionnaire:
demographics (sex, age, residence prior to hospitalization
[home vs. nursing home]), comorbidities (according to the
Charlson comorbidity index [CCI]) [15] and the Chronic
Disease Score (CDS) [16], neutropenia (defined as neu-
trophils \0.5 9 109/L), cardiovascular diseases (such as
coronary heart disease, history of myocardial infarction,
congestive heart failure, or valvular heart disease), risk
behavior (current alcoholism, smoking, injection drug
use; as assessed by the admitting physician), prior anti-
biotic treatment, clinical presentation, initial management
(imaging, lumbar puncture [if clinically indicated], blood
cultures, and the initialization of antimicrobial therapy; all
including the time period from the time of emergency room
[ER] admission), laboratory parameters (hemoglobin,
hematocrit, thrombocyte count, leucocyte count, blood urea
nitrogen, serum creatinine, C-reactive protein, blood glu-
cose, results from blood gas analysis), microbiology (sus-
ceptibility testing, serotyping), clinical course (systemic
inflammatory response syndrome [SIRS; defined as two or
more of the following: temperature (\36C or [38C);
heart rate [90 beats per min; respiratory rate [20 breaths
per min or paCO2 \ 4.3 kPa; leucocyte count\4,000/lL or
[12,000/lL], sepsis (defined as one or more blood culture
pairs positive), severe sepsis (defined as one or more blood
culture pairs positive AND single organ failure), septic
shock (defined as one or more blood culture pairs positive
AND multiple organ failure OR need for catecholamines)),
complications, and outcome (LOS, death). All times were
calculated in relation to the moment of ER admission.
Microbiological analyses
Antimicrobial susceptibility testing for penicillin and cef-
triaxone was performed according to the Clinical and
520 A.-M Giner et al.
123
Laboratory Standards Institute (CLSI) recommendations at
the Institute of Medical Microbiology, University of Zurich
[17]. S. pneumoniae was identified using standard meth-
odology, including colonial morphology on blood agar,
bile solubility, and susceptibility to optochin. Additionally,
all S. pneumoniae strains were then sent to the Swiss
National Reference Center for Invasive Pneumococci
(NRCP), where serotyping was carried out and suscepti-
bility testing against levofloxacin, erythromycin, and co-
trimoxazole was performed. Intermediate resistance was
categorized as ‘‘not susceptible’’.
Data management and statistical analyses
Data were entered into the EpiData Data Entry, Data
Management and Basic Statistical Analysis System 3.1
(EpiData Association, Odense, Denmark, 2008), and then
cleaned and manually inspected for errors and outlying
values, which were then confirmed or corrected with ori-
ginal records.
Differences in medians, for non-normally distributed
data, were analyzed using the Wilcoxon rank-sum test, and
differences in means, for normally distributed data, were
assessed using Student’s t-test. Differences in group pro-
portions were assessed and univariable analyses for risk
factors for death were performed using the Chi-square or
Fisher’s exact test, as appropriate. Multivariable analysis
assessing the risk of death was not possible due to the small
number of outcomes [18]. We used analysis of variance
(ANOVA) to build multivariable models including pre-
dictors associated with LOS, treating LOS as a continuous
variable.
All statistical analyses were performed using Stata 10.1
(StatCorp, College Station, TX, USA). A two-tailed test of




A total of 141 blood cultures were tested positive for
S. pneumoniae during the study period. Thirty-nine (27.7%)
episodes did not meet the inclusion criteria [hospital-
acquired infection: 10 (7.1%), transfer to another hospital
before the end of treatment: 25 (17.7%), referral from
another hospital: 8 (5.7%)]. Four (3.9%) patients had more
than one episode of pneumococcal bacteremia, resulting in
a total number of 102 episodes from 98 patients being
available for analysis.
Table 1 summarizes the patient characteristics. The
ratio of men to women was 1.4. The most common
comorbidities were: chronic liver disease (23.5%), cardio-
vascular disease (20.6%), chronic renal disease (16.7%),
human immunodeficiency virus (HIV) infection (13.7%),
chronic respiratory disease (12.7%), and diabetes mellitus
Table 1 Characteristics of 98 patients (102 episodes) with pneumo-
coccal bacteremia, 2003–2009
Variable Result
Number of episodes of pneumococcal bacteremia 102 (100)
Male gender 59 (57.8)
Age, median (IQR) 59.2 (46.8–71.0)
C60 years 47 (46.1)
Nursing home residence 7 (6.9)
Comorbidities
Chronic disease score, median (IQR) 4 (1–5)
Charlson comorbidity index, median (IQR) 2 (1–4)
Impaired immunity
Cellular immunodeficiency
HIV infection 14 (13.7)




Chronic disease of the respiratory tract 13 (12.7)
Cardiovascular disease 21 (20.6)
Diabetes mellitus 13 (12.7)
Chronic liver disease 24 (23.5)
Chronic renal disease 17 (16.7)
Concurrent medication




Injection drug use 5 (4.9)
Prior antibiotic treatment
For current episode 2 (2.0)
Within previous 6 months 21 (20.6)
Diagnosis at hospital admission
Pneumonia 61 (59.8)
Other infection of the lower respiratory tract 6 (5.9)
Meningitis or cerebral abscess 10 (9.8)
Sinusitis 1 (1.0)
Otitis media 4 (3.9)
Sepsis 8 (7.8)
Fever without focus 10 (9.8)
Deterioration of general health condition 7 (6.9)
Suppurative arthritis 3 (2.9)
Disease of the gastrointestinal tract 2 (2.0)
Other 6 (5.9)
Numbers are n (%) unless otherwise specified
IQR interquartile range
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(12.7%). Only in 35 cases (34.3%) was no risk behavior
(none of alcoholism, smoking, or injection drug use)
documented.
Patients presented with SIRS in 83 cases (81.3%). In 79
cases (77.5%), the bacteremia was classified as ‘‘sepsis’’, in
three cases (3.7%) as ‘‘severe sepsis’’, and in 20 cases
(19.6%) as ‘‘septic shock’’.
The most common diagnosis at discharge was pneu-
monia (73.5%), followed by meningitis (9.8%). The final
diagnoses of otitis media (3.9%), sinusitis (2.9%), and
sepsis without focus (1.0%) were less common. More than
one diagnosis was made in 7.8% of cases; combinations
were pneumonia and otitis media (3.9%), pneumonia and
meningitis (2.0%), and pneumonia and arthritis (2.0%).
Outcome
The median [interquartile range (IQR)] LOS was 10 (4–17)
days. In 31 (30.4%) cases, the patient had to be admitted to
the intensive care unit (ICU), where the median LOS (IQR)
was 4 (1–12) days. Sixteen (15.7%) of 98 patients died.
Antimicrobial susceptibility of pneumococcal isolates
Data regarding antimicrobial susceptibility could be obtained
for 84 (82.4%) isolates. Of five strains (6.0%) with decreased
susceptibility to penicillin, four were shown to have a mini-
mum inhibitory concentration (MIC) of between 0.12 mg/L
and 1 mg/L, and one had an MIC above 2 mg/L. All strains
were susceptible to ceftriaxone. Fifteen (17.9%) strains were
not susceptible to cotrimoxazole, eight (9.5%) strains were not
susceptible to erythromycin, and one (1.2%) strain was not
susceptible to levofloxacin.
Initial diagnostic procedures and time to antimicrobial
administration
The times to initial diagnostic procedures are depicted in
Table 2. The median time (IQR) to the first antibiotic dose
was 4.0 (2.0–5.9) h (Fig. 1). In 100 (98.0%) of 102 epi-
sodes, the initial antibiotic treatment regimen corresponded
to the local guidelines of the University Hospital Zurich.
Empirically administered antibiotics did not have antimi-
crobial activity against S. pneumoniae in two (2.0%)
episodes.
Risk factors for death
The following factors were associated with fatal outcome
in the univariable analysis: Charlson comorbidity index
[odds ratio (OR) (95% confidence interval) per unit
increase, 1.3 (1.1–1.6)], neutropenia [OR, 10.1 (2.0–51.0)],
HIV infection [OR 3.9 (1.1–13.8), chronic respiratory
disease (OR 4.4 (1.2–16.0)], chronic liver disease [OR 3.2








Blood culture 102 (100) 1.4 (0.5–3.3)
Chest radiograph 97 (95.1) 2.5 (1.2–4.2)
Lumbar puncture 11 (10.8) 4.2 (2.7–7.2)
Brain CT scan or MRI 22 (21.6) 2.3 (0.6–6.2)
CT computed tomography, MRI magnetic resonance imaging
Fig. 1 The time to initial antimicrobial treatment in patients with pneumococcal bacteremia and different initial diagnoses
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(1.0–9.7)], smoking [OR 3.8 (1.1–13.5)], injection drug use
[OR 9.7 (1.5–63.7)], and antibiotic therapy within the
previous 6 months before admission [OR 4.0 (1.3–12.5)]
(Table 3). There was no association between fatal outcome
and antimicrobial susceptibility rates (data not shown).
Overall, no association was found between the rapid
initiation of diagnostic steps and survival: the median time
(IQR) to blood culture (survivors: 1.3 (0.5–3.2) h vs.
deceased: 1.8 (1.2–5.5) h, P = 0.20), the median time
(IQR) to chest radiograph (survivors: 2.4 (1.2–4.0) h vs.
deceased: 2.8 (1.4–7.2) h, P = 0.59), and the median time
(IQR) to brain computed tomography (CT) scan or mag-
netic resonance imaging (MRI) (survivors: 1.65 (0.6–4.3) h
vs. deceased: 13.0 (5.0–116.6) h, P = 0.13) were not
different between survivors and deceased patients. Com-
pared to other initial diagnoses, the time to blood cultures
was decreased if patients were admitted with ‘‘pneumonia’’
(median time (IQR): 1.2 (0.5–2.7) h; P \ 0.001) or
‘‘meningitis or cerebral abscess’’ (median time (IQR): 0.8
(0.3–1.2) h; P = 0.016).
Deceased patients received their first dose of antibiotics
after a median time (IQR) of 3.3 (1.8–4.3) h, compared to
4.2 (2.0–5.9) h in survivors (P = 0.56) (Fig. 2). The initial
diagnosis did not affect the time to the first antibiotic dose
and there was no association between survival and the
rapid administration of initial antibiotic therapy; the case
fatality rate was 21.9% (7 of 32 episodes) if antibiotics
were administered within 4 h of ER admission and 12.5%
Table 3 Risk factors for death in 98 patients (102 episodes) with pneumococcal bacteremia
Characteristic Survivors (n = 86) Deceased (n = 16) OR (95% CI) P-value
Male gender 48 (55.8) 11 (68.8) 1.74 (0.56–5.44) 0.34
Age [60 years 40 (46.5) 7 (43.8) 0.89 (0.31–2.62) 0.90
Admitted from nursing home 4 (4.7) 3 (18.8) 4.73 (0.95–23.06) 0.06
Chronic disease score, median (IQR) 4 (2–5) 2 (0–5) 0.37
Charlson comorbidity index, median (IQR) 2 (1–3) 3 (2–7) 0.013
Co-morbidities
HIV infection 9 (10.5) 5 (31.3) 3.89 (1.10–13.75) 0.035
Immunosuppressive medication 8 (9.3) 1 (6.3) 0.58 (0.07–5.02) 0.62
Neutropenia 3 (3.5) 4 (25.0) 10.06 (1.98–51.02) 0.005
Splenectomy 4 (4.7) 0 (0.0) – 1.00
Chronic disease of the respiratory tract 8 (9.3) 5 (31.3) 4.43 (1.23–15.99) 0.023
Cardiovascular disease 19 (22.1) 2 (12.5) 0.50 (0.11–2.41) 0.39
Diabetes mellitus 11 (12.8) 2 (12.5) 0.97 (0.19–4.88) 0.97
Chronic liver disease 17 (19.8) 7 (43.8) 3.16 (1.03–9.69) 0.044
Chronic renal disease 15 (17.4) 2 (12.5) 0.68 (0.14–3.30) 0.63
Malignancy 3 (3.5) 2 (12.5) 3.95 (0.61–25.82) 0.15
Proton pump inhibitor therapy 16 (21.9) 4 (26.7) 1.30 (0.36–4.62) 0.69
Alcoholism 14 (16.3) 5 (31.3) 2.34 (0.70–7.78) 0.17
Smoking 29 (33.7) 9 (56.3) 3.80 (1.07–13.46) 0.038
Injection drug use 2 (2.3) 3 (18.8) 9.69 (1.48–63.65) 0.018
Antibiotic pretreatment for current episode 2 (2.3) 0 (0.0) – 1.00
Antibiotic therapy within previous 6 months 14 (16.3) 7 (43.8) 4.00 (1.27–12.53) 0.020
Initial diagnosis at the time of hospital admission
Infection of the respiratory tract 59 (68.6) 8 (50.0) 0.46 (0.16–1.35) 0.16
Meningitis or other CNS infection 7 (8.1) 3 (18.8) 2.60 (0.60–11.38) 0.20
Sinusitis or otitis media 4 (4.7) 1 (6.3) 1.37 (0.14–13.09) 0.79
Sepsis or fever without focus 13 (15.1) 3 (18.8) 2.27 (0.73–7.07) 0.16
SIRS 71 (82.6) 12 (75) 0.63 (0.18–2.24) 0.48
Inadequate empiric antibiotic therapy 2 (2.4) 0 (0.0) – 1.00
Delay of antibiotic therapy [4 h 31 (36.0) 6 (37.5) 0.51 (0.13–1.95) 0.33
Delay of antibiotic therapy [8 h 14 (16.3) 5 (31.3) 1.09 (0.20–5.90) 0.92
Numbers are n (%) unless otherwise specified
OR odds ratio, CI confidence interval, IQR interquartile range, CNS central nervous system
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(4 of 32 episodes) in patients who received their first
antibiotic dose more than 4 h after hospital admission
(P = 0.32).
Length of hospital stay
The following variables among those assessed as risk
factors for death (Table 3) were found to be associated
with an increase in the LOS among survivors: age
[60 years (median LOS (IQR) in patients aged[60 years:
11.5 (8.5–25.5) days vs. 6.0 (2.0–15.0) days in those aged
B60 years, P = 0.006), alcoholism (median LOS (IQR) in
patients reporting current alcoholism: 19.0 (13.0–30.0)
days vs. 9.0 (4.0–15.0) days in those not abusing alcohol,
P = 0.003), and admission diagnosis of ‘‘sepsis’’ (median
LOS (IQR) in patients admitted with ‘‘sepsis’’: 15.5
(9.0–29.0) days vs. 9.5 (4.0–15.5) days in those admitted
with other diagnoses, P = 0.028). There was no associa-
tion between the LOS and time to blood culture, time to
first antibiotic dose, time to imaging (chest radiograph or
brain CT/MRI), and time to lumbar puncture.
Multivariable analysis revealed age [60 years (P =
0.048) and alcoholism (P = 0.009) as independent pre-
dictors for an increase in the LOS.
Discussion
In this retrospective study of pneumococcal bacteremia in a
Swiss university hospital over a 6-year period, we were
unable to demonstrate an association between initial patient
management and fatal outcome and LOS, respectively.
Initial diagnostic steps and antimicrobial therapy were not
delayed in deceased patients, and 98% of patients received
an initial antimicrobial therapy that was adequate for
pneumococcal bacteremia according to local and interna-
tional guidelines. Factors associated with fatal outcome in
the univariable analysis were increasing comorbidity
scores, neutropenia, HIV infection, chronic respiratory
disease, chronic liver disease, smoking, injection drug use,
and previous antibiotic therapy in the past 6 months. Fac-
tors independently associated with prolonged LOS were age
[60 years and alcoholism.
We were unable to find other studies that assessed the
association between early diagnostic and therapeutic
management and survival in pneumococcal bacteremia.
Several studies have demonstrated that the earlier admin-
istration of antibiotics reduces mortality in community-
acquired pneumonia [6–8, 13]. There are, however, other
data indicating that the early administration of antibiotics
Fig. 2 Association between the time to the initial antibiotic treatment and fatal outcome in patients with pneumococcal bacteremia and different
initial diagnoses
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does not necessarily lead to better survival [19]. Similar to
our results, Cheng and Buising [19] observed that deceased
patients with community-acquired pneumonia received
their first dose of antibiotics after a median of 1.5 h, in
contrast to survivors who received their first dose of anti-
biotics after a median of 2.9 h. The authors hypothesized
that this finding may be due to either a true lack of asso-
ciation, in that minor differences in antibiotic administra-
tion within the first 8 h do not affect mortality, or to
confounding by severity because patients at the highest risk
of death were found to have received antibiotics earlier.
Overall, limitations of the available data result in a
continuing debate over the mandate to deliver antibiotics
within 4 h of arrival for patients being admitted to the
hospital with community-acquired pneumonia [20]. With
regards to our study, pneumococcal bacteremia is most
often secondary to infections of various organ systems that
differ in severity. Thereby, an advantage of survival would
be expected predominantly in those individuals who were
more severely ill, such as patients with CNS infection [21],
whereas the outcome of infections that develop over a
longer period of time may not be affected by differences in
the initiation of antimicrobial therapy, if this occurs within
a few hours [8].
Even though the median time to the first dose of anti-
biotics for pneumonia and meningitis observed in our study
met the proposed time limits from earlier publications
[11, 12], it has to be noted that a significant number of
patients received delayed initial antibiotic treatment in our
dataset. This may result from the wide range of possible
presentations of these patients, rendering initial diagnostic
and therapeutic choices difficult. Clinical deterioration may
be delayed especially in otherwise healthy subjects, pos-
sibly explaining the fact that patients at a higher risk for
death tend to receive diagnostic and therapeutic steps in a
more timely manner. Nevertheless, the overall case fatality
rate of 15.7% in our study is below average as compared to
other published data, which may be indicative of adequate
treatment quality given the case mix that is usually seen in
an academic center [1–5].
Our study has several limitations. First, the generaliz-
ability of our findings may be limited in that we present
results from a retrospective study of pneumococcal bac-
teremia conducted in a single university hospital in
Switzerland. The results may be different in other geo-
graphic areas and in non-academic centers. Second, our
study is limited by the lack of power, in that only 16
deceased patients were detected in a 6-year study period.
We were, thus, unable to perform multivariable analysis
assessing confounders of the possible association between
timely initial management and fatal outcome. Selection
bias might have crept in by excluding patients who were
transferred to another hospital or discharged before the
end of treatment. Patients treated over the entire course of
disease at an academic center likely have different char-
acteristics from those discharged on oral antibiotics or
transferred to secondary or tertiary hospitals for the
completion of treatment. The variability of the duration of
infection prior to presentation in the hospital is an addi-
tional confounding factor, which inherently renders the
interpretation of the findings regarding the interval between
hospital presentation and diagnostic and therapeutic
measures difficult. Last, the range of conditions varied
between the infection of cryptic origin to meningitis, and
the impact of delayed antibiotic administration in some of
these conditions may be less significant than others.
On the other hand, the existing literature suggests that
pneumococcal bacteremia, per se, is a strong indicator of
a serious clinical condition, irrespective of the origin, and,
thus, the variations in clinical conditions may be of less
importance [22].
The findings of this study confirm that pneumococcal
bacteremia is a disease with significant morbidity and
mortality requiring a timely and adequate initial manage-
ment. Our results indicate that there is a need for further
investigation to help identify patients presenting with
atypical clinical symptoms who may be at risk for delayed
initial diagnostic and therapeutic management. Larger
scale studies are needed in order to draw appropriate
conclusions about a mandate to deliver antibiotics within a
certain window of time after hospital admission in pneu-
mococcal bacteremia, and, particularly, to characterize
populations for which the adherence to such benchmarks
improves patient outcomes.
It has to be kept in mind that benchmarks do not
necessarily result in improved overall patient care
because care providers might focus too much on easily
measurable outcome data while neglecting other impor-
tant challenges. In the field of infectious diseases, an
excessively broad and thoughtless application of guide-
lines may have particularly negative consequences and,
at worst, may lead to an increase in adverse events or
bacterial resistance rates through an untimely and unnec-
essary use of antibiotics in viral or other non-bacterial
inflammatory diseases [23]. A study on the 4-h antibiotic
administration rule, without showing any reduction of
mortality, revealed that strict use of this benchmark
resulted in the misdiagnosis of pneumonia in almost 20%
of patients and, consecutively, to the inappropriate use of
antimicrobials [24, 25].
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